Medicinal compositions comprising buprenorphine and nalmefene
View Patent ↗An analgesic composition, in parenteral unit dosage form or in a unit dosage form suitable for delivery via the dermis or mucosa, comprises buprenorphine and an amount nalmefene such that the ratio by weight of buprenorphine to nalmefene delivered to or reaching the plasma of a patient is in the range 22.6:1 to 40:1. The analgesic action of the buprenorphine is potentiated by the low dose of nalmefene. Also provided are a method of treatment of pain and the use of nalmefene and buprenorphine for the manufacture of a medicament.
1. An analgesic composition, in parenteral unit dosage form or in a unit dosage form suitable for delivery via the mucosa or dermis, the composition comprising buprenorphine and an amount of nalmefene such that the ratio by weight of buprenorphine to nalmefene delivered to, or reaching the plasma of, a patient is in the range 23:1 to 40:1.
2. A composition as claimed in claim 1 , wherein the amount of buprenorphine in the unit dosage form is from 10 μg to 8 mg.
3. A composition as claimed in claim 1 , wherein the composition contains buprenorphine and nalmefene in a ratio of 23:1 to 36:1.
4. A method for the treatment of pain in a human patient, which method comprises the administration to a human patient, by a parenteral or dermal or mucosal route, of buprenorphine and nalmefene such that the ratio by weight of buprenorphine to nalmefene delivered to, or reaching the plasma of, a patient is in the range 23:1 to 40:1 for buprenorphine: nalmefene.
5. A method as claimed in claim 4 , wherein the administration of buprenorphine is in the range 0.25 to 640 μg per kg of body weight per 24 hours.
6. A composition as claimed in claim 1 , wherein the composition contains buprenorphine and nalmefene in a ratio of 24:1 to 32:1.
7. A composition as claimed in claim 1 , wherein the composition contains buprenorphine and nalmefene in a ratio of 25:1 to 30:1.